Ralph. H. Hruban - Cancer Science

Author Information

Ralph H. Hruban is a prominent figure in the field of cancer research, particularly focusing on pancreatic cancer. He is affiliated with the Department of Pathology and the Sol Goldman Pancreatic Cancer Research Center at the Johns Hopkins University School of Medicine in Baltimore, MD, USA. His extensive work has significantly contributed to advancements in understanding and treating pancreatic cancer.

Research Contributions

Ralph H. Hruban has made substantial contributions to cancer research, with a particular emphasis on pancreatic cancer. His work spans various aspects of the disease, from nodal staging and neoadjuvant therapy to genetic risk assessment and the natural history of intraductal papillary mucinous neoplasms. Notable among his recent publications are studies on the effectiveness of stereotactic body radiotherapy, the functional analysis of CDKN2A alleles, and the development of risk prediction tools for individuals with a family history of cancer. His research has been pivotal in improving pathologic outcomes and understanding the genetic underpinnings of pancreatic cancer.

Aliases

Ralph H. Hruban is also known by several aliases, including R.h. Hruban, R H. Hruban, Ralph Hruban, Ralpha H Hruban, and others. These variations appear in different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Publications	1304
Total Citations	158,689
h-index	198

Publications:

Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy

DOI: 10.1007/s00268-021-06410-y

Year: 2022

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity

DOI: 10.1245/s10434-021-11202-8

Year: 2022

Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance

DOI: 10.7554/eLife.71137

Year: 2022

A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.

DOI: 10.1038/s41416-021-01580-x

Year: 2021

ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer

DOI: 10.1245/s10434-021-10739-y

Year: 2021

Sa299 NATURAL HISTORY OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS: A PROSPECTIVE STUDY

DOI: 10.1016/S0016-5085(21)01842-4

Year: 2021

Long-term outcomes with neoadjuvant chemotherapy with or without stereotactic body radiation therapy in patients with borderline resectable and locally advanced pancreatic adenocarcinoma.

DOI: 10.1200/JCO.2021.39.3_SUPPL.443

Year: 2021

Current Status of Radiomics and Deep Learning in Liver Imaging

DOI: 10.1097/RCT.0000000000001169

Year: 2021

Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene.

DOI: 10.1001/jamaoncol.2021.3701

Year: 2021

Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer.

DOI: 10.1016/j.pan.2021.03.015

Year: 2021

What Legal Protections Exist Against Cancer-Related Discrimination?

What Mutations Affect SAC in Cancer?

How Do Power Naps Affect Cancer Treatment?

What are Pharmacological Treatments?

How Are Autoimmune Disorders Linked to Cancer?

What is Marginal Zone Lymphoma (MZL)?

How is a Diagnostic Test Validated?

Why is it Important to Share Personal Cancer Stories?

Can Herpes Infections Cause Cancer?

How Important Is Access to Cutting-Edge Therapies?

Partnered Content Networks

Relevant Topics